证券代码：600267 证券简称：海正药业 公告编号：临 2025-43 号 浙江海正药业股份有限公司 第十届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江海正药业股份有限公司（以下简称"公司"）第十届董事会第六次会 议于 2025 年 8 月 22 日下午在公司会议室以现场加通讯方式召开。应参加本次会 议董事 9 人，亲自参加会议董事 9 人，公司监事及高管人员列席了会议。本次会 议的召开程序符合《公司法》和《公司章程》的规定，会议合法有效。本次会议 由公司董事长肖卫红先生主持，经与会董事认真讨论研究，会议审议并通过了如 下决议： 一、关于计提资产减值准备的议案； 同意 9 票，反对 0 票，弃权 0 票。 详见《浙江海正药业股份有限公司关于计提资产减值准备的公告》，已登载 于 2025 年 8 月 26 日的《中国证券报》 《上海证券报》 《证券时报》和上海证券交 易所网站（www.sse.com.cn）上。 二、关于前期会计差错更正的议案； 同意 9 票，反对 0 票，弃权 0 票。 本议 ...

Core Viewpoint - Haizheng Pharmaceutical (600267) aims to adopt a differentiated strategy focusing on solidifying its industrial foundation, with emphasis on synthetic biology and high-end manufacturing [1] Group 1: Company Overview - Established in 1956, Haizheng Pharmaceutical started with raw materials and has evolved into a comprehensive pharmaceutical enterprise covering the entire value chain from research and production to sales [1] - The company operates a significant production base in Fuyang, Zhejiang, which spans over 1,500 acres and includes various subsidiaries [1] Group 2: Raw Material Business - The raw material segment is a traditional focus for Haizheng, leveraging technological and production scale advantages [2] - The company has developed over a hundred raw material drug varieties, utilizing a fermentation semi-synthesis technology platform [2] - Haizheng is expanding into the health sector, particularly in medical aesthetics and industrial raw materials, to enhance its sales capabilities [2] Group 3: Production Capabilities - Haizheng has established three major production bases in Taizhou, Fuyang, and Nantong, with a complete production line layout [2] - The Fuyang base features 17 independent production lines and adheres to a production philosophy of "pipeline, closed, continuous, and automated" [2] - The base has successfully secured CMO orders from international giants like Merck and continues to advance new product registrations [2] Group 4: Pharmaceutical Formulation Business - Haizheng has achieved a leading position in exporting injectable drugs to the U.S. market, maintaining high GMP standards [3] - The formulation business is primarily managed by its subsidiary, Hanhui Pharmaceutical, which has developed a unique quality management model [3] - Hanhui has successfully completed technology transfers for several original research products, addressing domestic supply shortages [3] Group 5: Animal Health Sector - The animal health segment is a key area of focus, with Haizheng leveraging its bases to create a diverse product matrix for livestock and pets [3] - Haizheng Animal Health has obtained multiple certifications and has several products with significant sales, including a record-breaking domestic deworming drug [3] - The company has a production capacity of 3,000 acres, allowing for strategic positioning in human and animal pharmaceuticals, both domestically and internationally [3]

Group 1 - The article highlights the global concern over hypertension, with approximately 1.3 billion people affected, and emphasizes the severe challenge in China where only 16% of the 250 million hypertensive patients achieve treatment targets [1] - The combination of hypertension and dyslipidemia significantly increases the risk of cardiovascular diseases, making effective management of both conditions a key focus in the industry [1] - The introduction of a compound drug named "Duodayi" represents a new paradigm in the combined treatment of hypertension and dyslipidemia, addressing the shortcomings of previous treatment methods [1][3] Group 2 - The compound formulation combines amlodipine and atorvastatin, which are well-known and widely used medications for hypertension and dyslipidemia, respectively [2] - Pfizer's early patent application for the combination in 1998 laid the groundwork for the development of the world's first dual-action compound drug, which received FDA approval in 2004 and has since been recognized globally [2][6] - The drug "Caduet" (Duodayi) has been approved in over 70 countries and has become a significant player in the cardiovascular medication market [2][6] Group 3 - The single-tablet formulation improves patient adherence to treatment, with a reported 26% increase in the proportion of patients maintaining treatment over 12 months compared to taking two separate medications [4] - The dual-action drug has shown a significant improvement in achieving both blood pressure and lipid level targets compared to single medications or free combinations [6] Group 4 - In July 2021, Haizheng Pharmaceutical began local production of Duodayi, maintaining original drug quality while reducing adverse reactions and treatment costs by 25% compared to single medications [7] - The drug is available in multiple dosages, allowing for tailored treatment plans based on individual patient needs, enhancing treatment efficiency [7] Group 5 - Haizheng Pharmaceutical emphasizes quality control and has implemented a comprehensive management system to ensure high standards in production, achieving FDA certification [8] - The company has adopted a digital transformation strategy, integrating modern information technology with advanced manufacturing processes to enhance the entire lifecycle of drug production [8][9] Group 6 - Duodayi is positioned as a solution for chronic disease management, simplifying medication regimens for patients and showcasing the potential of local pharmaceutical innovation [9] - The success of Duodayi reflects the growth and evolution of the Chinese pharmaceutical industry, demonstrating that local production can match or exceed the quality of original formulations [9]